Doctors across the United States who treat people with advanced prostate cancer can't find supplies of a medicine that may help them live longer.Pluvicto, a drug to treat metastatic castration-resistant prostate cancer, also known as mCRPC, is in such short supply that its maker, Novartis, said it cannot allow further supply until it can produce more of the drug.
#people #years #united-states #communications #news-release #side-effects #early-march #indianapolis #clinical-trials #side-effect
[
add
]
[
|
|
...
]